Abstract
Hepatoma Derived Growth Factor (HDGF) was originally identified as a secreted mitogen from the human hepatoma cell line Huh-7. Although initially thought to be a cytoplasmic protein, it became clear that HDGF is a nuclear targeted protein containing a canonical bipartite nuclear localization sequence. In the developing vasculature HDGF is highly expressed in the nucleus of smooth muscle and endothelial cells. HDGF expression in smooth muscle in particular, declines after birth in larger arteries only to be re-expressed with vascular injury in cells of the highly proliferative neointima. In addition, levels of HDGF have recently been shown to be elevated in a number of cancers, suggesting a potential role in cancer development. Because of these roles, HDGF is a potential target for drug design. This review will describe current knowledge about the biochemical functioning of the protein and identify potential avenues for drug development.
Keywords: vascular disease, pwwp, hdgf, growth factors
Current Drug Targets
Title: Hepatoma Derived Growth Factor is a Nuclear Targeted Mitogen
Volume: 4 Issue: 5
Author(s): Allen D. Everett and John Bushweller
Affiliation:
Keywords: vascular disease, pwwp, hdgf, growth factors
Abstract: Hepatoma Derived Growth Factor (HDGF) was originally identified as a secreted mitogen from the human hepatoma cell line Huh-7. Although initially thought to be a cytoplasmic protein, it became clear that HDGF is a nuclear targeted protein containing a canonical bipartite nuclear localization sequence. In the developing vasculature HDGF is highly expressed in the nucleus of smooth muscle and endothelial cells. HDGF expression in smooth muscle in particular, declines after birth in larger arteries only to be re-expressed with vascular injury in cells of the highly proliferative neointima. In addition, levels of HDGF have recently been shown to be elevated in a number of cancers, suggesting a potential role in cancer development. Because of these roles, HDGF is a potential target for drug design. This review will describe current knowledge about the biochemical functioning of the protein and identify potential avenues for drug development.
Export Options
About this article
Cite this article as:
Everett D. Allen and Bushweller John, Hepatoma Derived Growth Factor is a Nuclear Targeted Mitogen, Current Drug Targets 2003; 4 (5) . https://dx.doi.org/10.2174/1389450033490975
DOI https://dx.doi.org/10.2174/1389450033490975 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Autophagy and Ubiquitination as Two Major Players in Colorectal Cancer: A Review on Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Application and Future Prospect of Extracellular Matrix Targeted Nanomaterials in Tumor Theranostics
Current Drug Targets Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Osteogenic Differentiation of Orofacial Tissue-Derived Mesenchymal Stem Cells- A Review
Current Tissue Engineering (Discontinued) miRNAs in Gastrointestinal and Liver Cancers: Their Perspectives and Clinical Applications
Current Pharmaceutical Design Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Transcriptional Control of the Oxidative Stress Response and Implications of Using Plant Derived Molecules for Therapeutic Interventions in Cancer
Current Medicinal Chemistry Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein
Current Medicinal Chemistry Cardiovascular and Renovascular Implications of COX-2 Inhibition
Current Pharmaceutical Design Telocytes as a Source of Progenitor Cells in Regeneration and Repair Through Granulation Tissue
Current Stem Cell Research & Therapy Evaluation of the Anticancer Activities of the Plant Alkaloids Sanguinarine and Chelerythrine in Human Breast Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry A Comprehensive Review on Ethnomedicinal, Pharmacological and Phytochemical Basis of Anticancer Medicinal Plants of Pakistan
Current Cancer Drug Targets Pentapeptides as Minimal Functional Units in Cell Biology and Immunology
Current Protein & Peptide Science Hypothalamic Leptin and Ghrelin Signaling as Targets for Improvement in Metabolic Control
Current Pharmaceutical Design Targeting Matrix Metalloproteinases in Inflammatory Conditions
Current Drug Targets